Industry news
-
Nanoparticles for normal blood pressure
10 April 2019
Biologists in Novosibirsk, in Siberia, have developed special nanoparticles that are said to be able to lower blood pressure, and are reported to have successfully tested the drug candidate on hypertension afflicted rats.
-
Announcing of Formulary of Russian Pharmaceutical Manufacturers
10 April 2019
At the 2nd conference «Information technologies in pharmacy: the pharamceutical industry on its way to digital transformation», SID & GP announced drafting of the Formulary of Russian pharmaceutical manufacturers. It has appeared that such a summary digest with the data allowing for an unbiassed assessment of the industry is much in demand by pharmaceutical companies.
-
Going Global in Biopharma Regulatory Affairs
09 April 2019
The biopharmaceutical regulatory landscape is continually shifting and adapting, mirroring the innovative nature of the industry and ultimately ensuring the safety of all stakeholders. With increasing demands for globally accepted solutions to mitigate the rising development costs, further regulatory harmonization would undoubtedly be beneficial to patients and manufacturers.
-
New Class of Drugs to Stop Growing of Ovarian Cancer Cells
09 April 2019
A team of researchers across The University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.The Cancer Research UK and Wellcome Trust funded study, published in the journal Cancer Cell, showed that the drugs, called PARG inhibitors, can kill ovarian cancer cells by targeting weaknesses within their ability to copy their DNA.
-
Russian Biologists Show Benefits of Individual Approaches in Cancer Therapy
08 April 2019
A team of biologists from Sechenov First Moscow State Medical University and Lobachevsky University (Nizhny Novgorod) analyzed available methods of targeted drug delivery to malignant tumors. Individual approaches to cancer therapy limit the influence of drugs on healthy tissues and reduce side effects. The results of the study were published in the Cancers journal.
-
Pfizer uses real-world data to score Ibrance breast cancer nod in males
08 April 2019
Breast cancer is a rare disease in men, making it tough for drugmakers to conduct clinical trials. But Pfizer came up with a solution. The pharma giant scored a new nod Thursday for big-seller Ibrance in males, based largely on real-world evidence. Along the way, regulators studied data from electronic health records and post-marketing reports from the IQVIA Insurance database, the Flatiron Health Breast Cancer database and Pfizer's own global safety database.
-
Pharma's mammoth immunology market? It's only getting bigger: analysts
08 April 2019
Think the success of several megablockbusters such as AbbVie’s Humira means the anti-inflammation market is fully saturated? Think again. The autoimmune/inflammatory space has witnessed some of the best-selling drugs. But despite generally being considered crowded, the market still has a lot of room for growth, a team of Credit Suisse analysts said in a Wednesday note to clients.
-
Innovative Analytical Method for Identifying Counterfeit Drugs
05 April 2019
Medios AG, one of the leading Specialty Pharma companies in Germany, has rolled out its innovative analytical method for identifying counterfeit drugs following a successful trial period. Processing of the first customer orders will commence shortly. In addition, Medios has founded the subsidiary Medios Analytics GmbH in which all of the activities of the drug safety business unit are to be consolidated.
-
Research for Developing Easy to Swallow Meds
05 April 2019
Researchers at the University of Surrey and University of College London developed the test to examine how small multi-particulates can ease the travel of medicine from the mouth into the throat and body.
-
Effective manufacture of vaccines: the market of biopharmaceuticals in figures
04 April 2019
In Minpromtorg of Russia, a workshop on technology solutions for effective manufacture of vaccines is taking place. Equipment vendors, process engineers, developers of novel bioproducts as well as regulators discuss and share the experience of manufacture of such effective biotech products which allow for prevention, diagnostics and treatment of infectious and invasive diseases.
